Clinical Trials Browser

INDUSTRY × Ovarian Neoplasms × olaratumab × Clear all

NCT00913835 2019-09-26

A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer

Phase 2 Completed

125 enrolled 20 charts

Neoplasms, Ovarian Neoplasms